Market Intelligence, Clinical Progress, and High-Purity Reagents for Epigenetic and Oncological Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for BRPF1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | BRPF1 Bromodomain / Full-Length Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for biochemical binding assays. |
View BRPF1 Products |
| Gene Delivery | BRPF1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and cellular target engagement assays. |
View BRPF1 Products |
| Benchmark Ab | Anti-BRPF1 Recombinant Antibody Recombinant positive control for western blot, IHC, and IP validation. |
View BRPF1 Products |
| Validator | BRPF1 siRNA Set For knockdown verification and functional phenotypic validation. |
View BRPF1 Products |
| Related Target A | BRPF2 (BRD1) High homology paralog. Essential for counter-screening to ensure drug selectivity. |
View BRPF2 Products |
| Related Target B | BRPF3 Subfamily member involved in histone acetylation. Crucial for selectivity profiling. |
View BRPF3 Products |
| Related Target C | KAT6A (MOZ) Catalytic core of the histone acetyltransferase complex scaffolded by BRPF1. |
View KAT6A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Paralog Off-Target Profiling (BRPF2/BRPF3) | Highly purified BRPF1, BRPF2, and BRPF3 bromodomain proteins available with >95% purity verified by SDS-PAGE. |
| Assay Interference & False Positives | Sequence verified constructs with strict endotoxin control (<1.0 EU/μg) to prevent non-specific cellular toxicity. |
| Lack of Controls | Recombinant benchmark antibodies and validated siRNA sets included for target validation. |
| Cellular Target Engagement | High-titer Lentiviral particles for robust, stable expression of full-length BRPF1 in target cancer cell lines. |
Live BRPF1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for BRPF1 therapeutics is intensifying, with major players shifting focus from traditional multi-HAT inhibitors to highly selective BRPF1 bromodomain inhibitors and PROTAC degraders. As first-generation epigenetic therapies reach the clinic, the next wave of R&D is targeting pediatric leukemia (specifically MOZ-TIF2 driven AML), medulloblastoma, and certain solid tumors where BRPF1 acts as a master scaffold for oncogenic histone acetyltransferase complexes.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Bayer, GSK, Academic Consortia | Acute Myeloid Leukemia (AML), Solid Tumors | High-throughput screening (HTS) using pure, recombinant BRPF1 Bromodomain proteins. |
| PROTAC Degraders | Various Biotech Startups | Advanced Solid Tumors, Hematological Malignancies | Cellular degradation assays requiring Lentivirus-mediated stable BRPF1-reporter cell lines. |
| Combination Therapies | Clinical Trial Sponsors | Drug-Resistant Cancers | Synergy validation utilizing BRPF1 siRNA knockdown alongside standard chemotherapeutics. |